Biocon Limited (NSE: BIOCON) announced that its Pertuzumab biosimilar has become the first biosimilar to secure a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval recommendation under the new tailored clinical approach marks a significant milestone for Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited. The biosimilar, marketed under the brand name Pebrilzo®, is indicated for the treatment of HER2-positive breast cancer across multiple disease stages.

Extensive Clinical and Analytical Validation

The positive CHMP opinion follows a comprehensive review of the marketing authorization application submitted by Biocon Biologics Ireland Limited. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Pebrilzo® is highly similar to the reference biologic, with no clinically meaningful differences in quality, safety, or efficacy.

Expanding Access to Biologic Therapies

Shreehas Tambe, CEO & Managing Director of Biocon, said: “The positive CHMP opinion for our Pertuzumab biosimilar marks an important step toward expanding access to biologic therapies for patients with HER2-positive breast cancer in Europe.” This approval reflects an important milestone in the evolution of biosimilar science and greater regulatory confidence on advanced analytical and clinical pharmacology evidence to establish biosimilarity.

As the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA’s tailored clinical development approach, this approval is a testament to Biocon’s commitment to providing affordable, life-changing medicines to patients worldwide.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 44% of its 52-week range with RSI at 35. In other words, neither side has a clear edge right now. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Biocon Limited (NSE: BIOCON) has announced the signing of a 10-year supply contract for Pertuzumab in Brazil, marking a significant milestone in advancing HER2-positive breast cancer therapy. The contract was signed with Bahiafarma and Bionovis, under Brazil’s Productive Development Partnership (PDP) program. The consortium received 100% allocation under Brazil’s 10-year PDP program for Pertuzumab, providing exclusive access to Brazil’s public healthcare market.

Strategic Partnership

Shreehas Tambe, CEO & Managing Director of Biocon, emphasized the transformative potential of strong partnerships in building local capabilities and expanding access to affordable medicines. This contract enables Biocon to reach more patients with HER2-positive breast cancer and address an important healthcare need at scale.

Market Impact

The PDP framework supports the long-term adoption of Biocon’s product within Brazil’s public oncology network. The product will undergo phased localization in Brazil in the mid to long term, ensuring sustainable access to this important cancer therapy. This partnership also contributes to Brazil strengthening its capacity to produce essential medicines for its Unified Health System (SUS).

Future Prospects

As part of the PDP, Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over a 10-year period. This agreement not only supports better patient outcomes but also helps build a stronger, more resilient healthcare ecosystem in Brazil.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 18 of recent sessions versus 12 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Dishman Carbogen Amcis Limited (DCAL) has reported its financial results for the first quarter of FY27, revealing a net revenue of ₹6,776 million, a slight decline of 4.29% compared to ₹7,080 million in Q1FY26. The decrease is primarily attributed to a deferment of CDMO revenue, partially offset by growth in the Marketable Molecules (MM) segment.

Quarter Highlights

The CDMO revenue experienced a 12.6% year-over-year decline, mainly due to customer-requested rescheduling of project deliverables worth approximately CHF 10 million to the second half of the financial year. In contrast, the MM segment revenue surged by 48% in Q1 FY27 compared to Q1 FY26, driven by higher Cholesterol revenue.

Segment Performance

The EBITDA margin for the quarter stood at 8.9%, significantly down from 19.9% in Q1 FY26. The CDMO segment margin dropped to 6.3% from 17.9% in the same quarter last year due to deferred revenues and a notional foreign exchange loss of INR 117.3 million. Meanwhile, the MM segment margin declined to 18.6% from 32.4%, primarily due to higher sales of Cholesterol compared to Vitamin D Analogues.

Forward Outlook

Despite the current challenges, Dishman Carbogen Amcis Limited remains focused on improving capacity utilization by targeting small and mid-sized global biotech companies and diversifying across new geographies. The company continues to leverage its robust R&D capabilities and global presence to drive future growth.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Dishman moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock holds at 32% of its 52-week range with RSI at 51. In other words, neither side has a clear edge right now. Revenue grows at 8.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dishman Carbogen Amcis Limited.